BNY Mellon Investment Management has added a fund focused on healthcare biotechnology to its innovation fund range, to be managed by Mellon Investments Corporation.
The BNY Mellon Smart Cures Innovation fund is part of the Irish-domiciled fund range, BNY Mellon Global Funds, with Mellon's Amanda Birdsey-Benson and Matthew Jenkin named as co-managers. It will invest in companies that are developing gene therapy, gene editing and gene modulation treatments, as well as those helping to fuel the development of these drugs. The vehicle joins the group's existing innovation thematics range, which already includes the BNY Mellon Mobility Innovation and BNY Mellon Blockchain Innovation funds. IW Long Reads: Is Vaccine Mania In Danger Of Creating The N...
To continue reading this article...
Join Investment Week for free
Signup and gain exclusive members-only insights - all free of charge!
- Unlimited access to real-time news, analysis and opinion from the investment industry, including the Sustainable Hub covering fund news from the ESG space
- Get ahead of regulatory and technological changes affecting fund management
- Important and breaking news stories selected by the editors delivered straight to your inbox each day
- Weekly members-only newsletter with exclusive opinion pieces from leading industry experts
- Be the first to hear about our extensive events schedule and awards programmes
